[{"id":"4e146a44-d064-44ac-94c6-9a5142727e36","acronym":"ZUMA-12","url":"https://clinicaltrials.gov/study/NCT03761056","created_at":"2022-07-08T22:54:07.243Z","updated_at":"2024-07-02T16:35:30.615Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma","source_id_and_acronym":"NCT03761056 - ZUMA-12","lead_sponsor":"Kite, A Gilead Company","biomarkers":" IFNG • IL6 • CXCL8 • GZMB • IL5 • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • CXCL8 • GZMB • IL5 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 05/17/2021","primary_completion_date":" 05/17/2021","study_txt":" Completion: 10/12/2023","study_completion_date":" 10/12/2023","last_update_posted":"2023-11-02"},{"id":"23758911-8745-4e04-b970-f675198d8588","acronym":"PRINCESS","url":"https://clinicaltrials.gov/study/NCT05821751","created_at":"2023-04-20T14:03:53.992Z","updated_at":"2024-07-02T16:35:50.012Z","phase":"","brief_title":"The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT05821751 - PRINCESS","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 12/02/2024","primary_completion_date":" 12/02/2024","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2023-04-20"},{"id":"398611ec-32d5-4767-9ab0-d167a02f0c96","acronym":"ICE","url":"https://clinicaltrials.gov/study/NCT05727813","created_at":"2023-02-14T18:02:36.078Z","updated_at":"2024-07-02T16:35:55.606Z","phase":"","brief_title":"To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study)","source_id_and_acronym":"NCT05727813 - ICE","lead_sponsor":"University of Roma La Sapienza","biomarkers":" IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2RA • CXCL9 • IL10 • HMGB1 • CCL11 • CCL2 • IL17A • CCL3 • IL13 • IL15 • IL1R1 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/16/2023","primary_completion_date":" 01/16/2023","study_txt":" Completion: 01/27/2023","study_completion_date":" 01/27/2023","last_update_posted":"2023-02-14"},{"id":"e4dfc3e3-609f-407a-81af-e186b7ede706","acronym":"","url":"https://clinicaltrials.gov/study/NCT03905135","created_at":"2021-01-18T19:13:31.837Z","updated_at":"2024-07-02T16:36:04.092Z","phase":"Phase 1","brief_title":"Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies","source_id_and_acronym":"NCT03905135","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • IL15 • IL5","pipe":" | ","alterations":" PD-L1 expression","tags":["TNFRSF8 • IL15 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 03/25/2021","primary_completion_date":" 03/25/2021","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-09-13"},{"id":"32c24bdb-718c-4a35-a172-afb3477afdce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05535673","created_at":"2022-09-10T11:56:30.321Z","updated_at":"2024-07-02T16:36:04.124Z","phase":"Phase 1","brief_title":"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma","source_id_and_acronym":"NCT05535673","lead_sponsor":"Zhengzhou University","biomarkers":" BCL2 • BCL6 • IL6 • CXCL8 • IL2 • IL10 • IL17A • IL22 • IL4 • IL5","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • IL6 • CXCL8 • IL2 • IL10 • IL17A • IL22 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ThisCART19A"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-09-12"},{"id":"024e1277-d133-4914-a627-57cfe108a970","acronym":"TruCulture","url":"https://clinicaltrials.gov/study/NCT04127864","created_at":"2021-01-18T20:09:51.316Z","updated_at":"2024-07-02T16:36:05.964Z","phase":"","brief_title":"Perioperative Immune Function in Patients Undergoing Colorectal Cancer Surgery","source_id_and_acronym":"NCT04127864 - TruCulture","lead_sponsor":"University of Copenhagen","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CCL2 • CSF2 • IL17A • IL13 • IL1B • IL4 • IL5 • IL7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/14/2019","start_date":" 10/14/2019","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-08-05"},{"id":"66e0fc5a-b053-47ce-b084-660c0c6c06be","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696056","created_at":"2021-01-18T18:06:55.792Z","updated_at":"2024-07-02T16:36:38.964Z","phase":"","brief_title":"Improving Brain Function After Breast Cancer Study","source_id_and_acronym":"NCT03696056","lead_sponsor":"University of Texas at Austin","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL13 • IL4 • IL5 • IL7","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL13 • IL4 • IL5 • IL7"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/30/2020","study_completion_date":" 01/30/2020","last_update_posted":"2020-11-09"},{"id":"6a27cba9-7ec4-4d78-9a46-d7f5c6448719","acronym":"","url":"https://clinicaltrials.gov/study/NCT04345978","created_at":"2021-01-18T21:01:45.006Z","updated_at":"2024-07-02T16:36:42.078Z","phase":"","brief_title":"Effects of Fasting Strategies on Postoperative Recovery and Long-term Prognosis in Patients With Colorectal Cancer","source_id_and_acronym":"NCT04345978","lead_sponsor":"Fudan University","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • IL17A • IL1B • IL4 • IL5 • CA 19-9","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • IL17A • IL1B • IL4 • IL5 • CA 19-9"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2400","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2020-08-11"},{"id":"333965c4-6c89-43f0-ad5b-8e2544276d05","acronym":"","url":"https://clinicaltrials.gov/study/NCT03331367","created_at":"2021-01-18T16:27:04.596Z","updated_at":"2024-07-02T16:36:42.214Z","phase":"","brief_title":"Investigating and Characterizing the Immune Response to Prostate Cancer","source_id_and_acronym":"NCT03331367","lead_sponsor":"NYU Langone Health","biomarkers":" IFNG • IL6 • TNFA • CXCL8 • IL2RA • IL2 • IL10 • IL13 • IL1B • IL4 • IL5 • ISG20","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • CXCL8 • IL2RA • IL2 • IL10 • IL13 • IL1B • IL4 • IL5 • ISG20"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/14/2017","start_date":" 09/14/2017","primary_txt":" Primary completion: 02/25/2020","primary_completion_date":" 02/25/2020","study_txt":" Completion: 02/25/2020","study_completion_date":" 02/25/2020","last_update_posted":"2020-08-07"},{"id":"e90d90e5-33e6-4be3-bd2c-8d8dccd30023","acronym":"","url":"https://clinicaltrials.gov/study/NCT04355806","created_at":"2021-01-18T21:03:23.571Z","updated_at":"2024-07-02T16:36:45.824Z","phase":"","brief_title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","source_id_and_acronym":"NCT04355806","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2020-04-21"},{"id":"b7ba8800-4b93-44de-a6a9-58fc7d2030c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00086242","created_at":"2021-01-18T00:15:08.039Z","updated_at":"2024-07-02T16:37:02.125Z","phase":"","brief_title":"Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer","source_id_and_acronym":"NCT00086242","lead_sponsor":"University of California, Irvine","biomarkers":" IFNG • IL10 • IL5","pipe":"","alterations":" ","tags":["IFNG • IL10 • IL5"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 08/01/2004","start_date":" 08/01/2004","primary_txt":" Primary completion: 12/31/2005","primary_completion_date":" 12/31/2005","study_txt":" Completion: 06/30/2007","study_completion_date":" 06/30/2007","last_update_posted":"2019-03-08"},{"id":"a3660b0c-6ed3-4249-9b3d-fdf23e01573d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00640861","created_at":"2021-01-18T02:23:05.773Z","updated_at":"2024-07-02T16:37:05.719Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer","source_id_and_acronym":"NCT00640861","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • CD8 • IFNG • MUC1 • CD4 • IL5","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • PGR expression • HLA-A2 positive","tags":["HER-2 • CD8 • IFNG • MUC1 • CD4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • PGR expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2/neu peptide vaccine • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 08/28/2008","start_date":" 08/28/2008","primary_txt":" Primary completion: 04/21/2015","primary_completion_date":" 04/21/2015","study_txt":" Completion: 04/21/2015","study_completion_date":" 04/21/2015","last_update_posted":"2018-10-31"},{"id":"9571bff7-45a4-4092-9335-e996a04d4d27","acronym":"","url":"https://clinicaltrials.gov/study/NCT00058526","created_at":"2021-01-18T00:07:31.892Z","updated_at":"2024-07-02T16:37:22.221Z","phase":"Phase 1","brief_title":"A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer","source_id_and_acronym":"NCT00058526","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2 • IFNG • CD4 • IL5","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • IFNG • CD4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dHER2+AS15"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 03/20/2003","start_date":" 03/20/2003","primary_txt":" Primary completion: 09/06/2006","primary_completion_date":" 09/06/2006","study_txt":" Completion: 09/06/2006","study_completion_date":" 09/06/2006","last_update_posted":"2017-05-15"},{"id":"c7cb12bd-00a5-4666-8ffc-015f0ac907fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03093623","created_at":"2021-01-18T15:14:29.764Z","updated_at":"2024-07-02T16:37:23.535Z","phase":"","brief_title":"The Effect of Physical Activity and Abstain From Smoking on the Precancerous Lesion","source_id_and_acronym":"NCT03093623","lead_sponsor":"Taipei Medical University","biomarkers":" IL2 • IL10 • TNFRSF1A • IL13 • IL4 • IL5","pipe":"","alterations":" ","tags":["IL2 • IL10 • TNFRSF1A • IL13 • IL4 • IL5"],"overall_status":"Unknown status","enrollment":" Enrollment 446","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-04-11"},{"id":"08338ec0-6078-48e0-bc33-7c4d40eba740","acronym":"MEL58","url":"https://clinicaltrials.gov/study/NCT01585350","created_at":"2021-01-18T06:45:23.070Z","updated_at":"2024-07-02T16:37:29.831Z","phase":"Phase 1","brief_title":"A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients","source_id_and_acronym":"NCT01585350 - MEL58","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5","pipe":"","alterations":" ","tags":["MYD88 • CD8 • IFNG • TNFA • CXCL12 • CXCL9 • CD4 • CD69 • IL2 • CXCL13 • IL10 • CCL19 • FOXP3 • IL17A • IL23A • CCL21 • GATA3 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-08-12"}]